QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Lung function (FEV₁) Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Change in SGRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Lung function (FEV₁) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Time to first moderate or severe exacerbation All participants · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).
1 finding from 1 review
Lung function (FEV₁) Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring emergency department treatment or admission · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations All… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in SGRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Dental caries susceptibility · Ethnicity: Caucasian (n=2) individuals with caries/high caries and controls
The pooled odds ratio was 2.80 (95% CI 0.93 to 8.43).
1 finding from 1 review
OR 2.80 [0.93, 8.43]
2 studies
GRADE not reported
Dental caries susceptibility · Ethnicity: Asian (n=2) individuals with caries/high caries and controls
The pooled odds ratio was 0.90 (95% CI 0.23 to 3.63).
1 finding from 1 review
OR 0.90 [0.23, 3.63]
2 studies
GRADE not reported
Dental caries susceptibility · Individuals assessed for dental caries (cases with caries/high caries vs. caries-free or low/very-low-caries controls)
The pooled odds ratio was 0.92 (95% CI 0.24 to 3.58).
1 finding from 1 review